Noninvasive bioelectric therapy for dry AMD enters pivotal trial

Written by The Life Science Feed Editorial Team · Published 19 August 2026 · Edited by Mara Voss

> Dry age-related macular degeneration (AMD) remains a leading cause of irreversible vision loss in older adults, with limited treatment options available. While anti-VEGF injections have transformed care for wet AMD, patients with the dry form often face a progressive decline in central vision without an approved therapy to halt or reverse the process. A new noninvasive bioelectric therapy is now entering a study that will determine its efficacy and safety for regulatory approval, aiming to fill this significant clinical gap.

KEY TAKEAWAYS

- The Pivot: A noninvasive bioelectric device is being evaluated in a pivotal study for dry AMD, a condition with no approved disease-modifying treatments.
- The Data: No specific numeric results are available yet, as the therapy is in early-stage pivotal investigation.
- The Action: Clinicians should monitor developments in non-pharmacological interventions for dry AMD, as new modalities may emerge to address this unmet need.

Dry age-related macular degeneration affects millions globally, characterized by the accumulation of drusen and geographic atrophy in the macula. This progressive neurodegenerative condition of the retina leads to central vision impairment, severely impacting quality of life. Current management primarily focuses on lifestyle modifications and nutritional supplements, particularly the AREDS formulation, which can slow progression in some intermediate cases but does not restore lost vision or treat advanced disease.

The lack of effective treatments for dry AMD represents a substantial unmet medical need. Patients often experience a gradual but relentless decline in their ability to read, recognize faces, and perform daily activities. This burden extends beyond the individual, impacting caregivers and healthcare systems. The development of any therapy that could slow or stop the progression of geographic atrophy would be a significant advance.

A New Approach to Macular Degeneration

The investigational therapy utilizes a noninvasive bioelectric approach, delivered via a device designed to be used at home. This method aims to stimulate cellular processes within the retina, potentially mitigating the degeneration characteristic of dry AMD. The underlying principle involves modulating cellular activity through targeted electrical fields, an area of research gaining traction across various neurodegenerative conditions.

This study, which will determine if the therapy can gain regulatory approval, will evaluate the device's ability to preserve or improve visual function and reduce the progression of geographic atrophy. The trial design typically involves a placebo or sham control group to rigorously assess the device's efficacy against the natural history of the disease. Endpoints

commonly include changes in best-corrected visual acuity (BCVA), lesion size, and patient-reported outcomes related to vision quality.

The Clinical Rationale

The rationale for bioelectric stimulation in dry AMD stems from preclinical and early clinical observations suggesting that electrical fields can influence retinal cell health and function. These effects may include enhancing mitochondrial activity, reducing oxidative stress, and promoting the survival of photoreceptors and retinal pigment epithelial cells. Such mechanisms are critical, given the pathophysiology of dry AMD, which involves chronic inflammation, oxidative damage, and cellular dysfunction.

But the precise mechanisms by which bioelectric therapy might exert its effects in the complex environment of the degenerating retina are still under investigation. Early studies have explored various parameters of electrical stimulation, including frequency, intensity, and duration, to optimize potential therapeutic benefits. The noninvasive nature of this device offers a distinct advantage over intravitreal injections or surgical interventions, potentially improving patient adherence and reducing treatment burden.

The success of the study, which will determine if the therapy can gain regulatory approval, hinges on demonstrating a clinically meaningful benefit that outweighs any potential risks. For a condition like dry AMD, even a modest slowing of disease progression would be considered valuable. Clinicians often discuss the benefits of anti-VEGF therapies for wet AMD, but the conversation for dry AMD patients remains largely about managing expectations and supporting low vision. For a broader overview of ophthalmic conditions, the Oxford Handbook of Ophthalmology provides a concise reference.

What the Trial Aims to Show

The study, which will determine if the therapy can gain regulatory approval, is designed to provide definitive evidence on the efficacy and safety of this bioelectric therapy. It will enroll a large cohort of patients with intermediate to advanced dry AMD, including those with geographic atrophy. The primary outcome measures will likely focus on changes in visual acuity and the rate of progression of geographic atrophy, as measured by imaging techniques such as optical coherence tomography (OCT).

Secondary endpoints will include assessments of contrast sensitivity, reading speed, and quality of life questionnaires. Safety monitoring will be rigorous, looking for any adverse events related to device use. The long-term durability of any observed effects will also be a critical consideration, as dry AMD is a chronic, progressive condition. This trial builds on earlier exploratory work, much like how stereotactic radiotherapy has been investigated for nAMD to reduce injection burden.

The open-label design of some earlier studies is an obvious caveat, as patient and investigator expectations can influence subjective outcomes. A well-designed, sham-controlled study that will determine if the therapy can gain regulatory approval is essential to provide unbiased data. The trial will need to demonstrate not just statistical significance, but also clinical relevance, meaning the observed benefits must translate into tangible improvements in patients' daily lives.

The development of novel therapies for dry AMD is a high-priority area, given the aging global population and the increasing prevalence of the disease. While this bioelectric therapy is still investigational, its progression to a study that will determine if the therapy can gain regulatory approval signals a potential new avenue for treatment. The field has

seen other non-pharmacological interventions, such as semaglutide's potential impact on AMD risk, but direct treatment for dry AMD remains elusive.

CLINICAL IMPLICATIONS

The initiation of a study that will determine if the therapy can gain regulatory approval for a noninvasive bioelectric therapy in dry AMD offers a glimmer of hope for a patient population with severely limited options. For too long, the conversation with patients has been about managing decline rather than offering a proactive treatment. If successful, this device could fundamentally alter that discussion, providing a much-needed intervention.

Clinicians should remain cautiously optimistic. The history of AMD research is littered with therapies that showed early positive results but failed to deliver in larger trials. But a noninvasive, home-use device could significantly reduce the treatment burden compared to more invasive approaches, potentially improving adherence and accessibility for a chronic condition.

The key will be the magnitude and durability of any observed benefit. Even a modest slowing of geographic atrophy progression would be clinically meaningful, given the current lack of alternatives. We need to see clear evidence of improved visual function or a substantial reduction in the rate of vision loss, not just surrogate endpoints.

Should this therapy prove effective, it would represent a significant shift in the dry AMD treatment market. It would also open the door for further research into bioelectric modulation for other retinal degenerations, potentially expanding the therapeutic toolkit beyond pharmacological agents.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Guymer RH, Campbell TG. Age-related macular degeneration. Lancet. 2023;401(10386):1459-1472. doi:10.1016/S0140-6736(22)02609-5
2. 2. Thomas CJ, Mirza RG, Gill MK. Age-Related Macular Degeneration. Med Clin North Am. 2021;105(3):473-491. doi:10.1016/j.mcna.2021.01.003
3. 3. Girgis S, Lee LR. Treatment of dry age-related macular degeneration: A review. Clin Exp Ophthalmol. 2023;51(8):835-852. doi:10.1111/ceo.14294
4. 4. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728-38. doi:10.1016/S0140-6736(12)60282-7
5. 5. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147-1159. doi:10.1016/S0140-6736(18)31550-2
6. 6. Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J. Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review. Clin Ther. 2021;43(10):1792-1818. doi:10.1016/j.clinthera.2021.08.011

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com